Materias dentro de su búsqueda.
Mostrando 1,161 - 1,180 Resultados de 1,900 Para Buscar '"AstraZeneca"', tiempo de consulta: 0.78s Limitar resultados
  1. 1161
    por Jain, Rajeev
    Publicado 2015
    “…Results from ongoing CV outcome trials with other DPP-4 inhibitors may provide additional data on how best to manage patients with T2DM who are at risk for heart failure. FUNDING: AstraZeneca LP. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12325-015-0262-9) contains supplementary material, which is available to authorized users.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
  2. 1162
    “…The impact of the new guidance will be difficult to detect among the overall infant population, particularly in settings without routine testing for RSV, but the impact will be substantial for the small high-risk population affected by the changes. FUNDING: AstraZeneca. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40121-015-0097-3) contains supplementary material, which is available to authorized users.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Modeling the Potential Impact of the 2014 American Academy of Pediatrics Respiratory Syncytial Virus Prophylaxis Guidance on Preterm Infant RSV Outcomes
  3. 1163
    “…TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00877890. FUNDING: AstraZeneca.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment
  4. 1164
    “…CONCLUSION: These analyses suggest that treatment with naloxegol improves patients’ health state utility; driven predominantly by the relief of patients’ constipation. FUNDING: AstraZeneca.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients’ Health State Utility
  5. 1165
    “…TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT00121641, NCT00316082, NCT00698932, NCT00918879, NCT00121667, NCT00661362, NCT00313313, NCT00295633, NCT00757588. FUNDING: AstraZeneca, Gaithersburg, MD, USA.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment
  6. 1166
    “…Further research is needed to validate these findings in other T2D patient populations. Funding: AstraZeneca Pharmaceuticals.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
  7. 1167
    “…PLANNED OUTPUTS: Peer review publication reporting the real world lessons for clinical practice. FUNDING: AstraZeneca.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
  8. 1168
    por Ding, Bo, Small, Mark
    Publicado 2017
    “…CONCLUSION: Mild asthma imposes a substantial burden on patients, establishing the need for comprehensive management plans and ongoing support for treatment adherence. FUNDING: AstraZeneca.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Disease Burden of Mild Asthma: Findings from a Cross-Sectional Real-World Survey
  9. 1169
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan
  10. 1170
    “…INTRODUCTION: Exenatide once weekly (ExeOW, Bydureon(®), Astra Zeneca), a drug belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, is the first agent approved for treatment of type 2 diabetes (T2D) that can be administered on a weekly basis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes
  11. 1171
    “…CONCLUSION: Saxagliptin is efficacious and well tolerated in a real-world practice setting, with almost 80% of participants remaining on treatment after 2 years. FUNDING: AstraZeneca, France.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study
  12. 1172
    “…Halasa, sanofi pasteur: Research Contractor, Research support; Astra Zeneca: Research Contractor, Grant recipient…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    WHO Severe Acute Respiratory Infections (SARI) Definition often Underdiagnoses Serious Respiratory Viral Infections in Hospitalized Jordanian Children
  13. 1173
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A metabolic function of FGFR3-TACC3 gene fusions in cancer
  14. 1174
    “…Importantly, the β secretase inhibitor AZD3839-AstraZeneca significantly rescued the abnormal early electrophysiological phenotype of J20 mice. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Alzheimer’s Transgenic Model Is Characterized by Very Early Brain Network Alterations and β-CTF Fragment Accumulation: Reversal by β-Secretase Inhibition
  15. 1175
    “…We also tested two FGFR inhibitors; OVPA8 cells were resistant to AZD4547 (AstraZeneca, London, UK), but sensitive to the new inhibitor CPL304-110-01 (Celon Pharma, Łomianki/Kiełpin, Poland). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8
  16. 1176
    “…Compared with metformin monotherapy, initial combination therapies with DPP-4 inhibitors plus metformin, sodium/glucose cotransporter 2 inhibitors and metformin, respectively, were associated with similar risks of hypoglycemia, but initial combination therapies with sulfonylurea plus metformin, thiazolidinedione and metformin, respectively, were associated with higher risks of hypoglycemia. FUNDING: AstraZeneca Ltd. (China). TRIAL REGISTRATION: Registration number CRD42017060717 in PROSPERO. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis
  17. 1177
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers
  18. 1178
    “…[Image: see text] The metabotropic glutamate receptor subtype mGluR5 has been proposed as a potential drug target for CNS disorders such as anxiety, depression, Parkinson’s disease, and epilepsy. The AstraZeneca compound AZD9272 has previously been labeled with carbon-11 and used as a PET radioligand for mGluR5 receptor binding. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Synthesis, Biodistribution, and Radiation Dosimetry of a Novel mGluR5 Radioligand: (18)F-AZD9272
  19. 1179
    “…From 2005 statin-positive as well as statin-critical research was mainly sponsored by multinational pharmaceutical companies, predominantly Merck, AstraZeneca and Pfizer. In conclusion, the initial hypothesis about dedicated journals and sponsors was entirely substantiated at the general topical level and at the journal level of research disagreement, but not at sponsor level. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Do journals and corporate sponsors back certain views in topics where disagreement prevails?
  20. 1180
    “…Despite the impressive clinical trial results of the BNT162b2 (Pfizer/BioNTech), ChAdOx1 nCoV-19 (Oxford/AstraZeneca), and mRNA-1273 (Moderna) vaccines, important unanswered questions remain, especially in patients with pre-existing conditions. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement
Herramientas de búsqueda: RSS